KR102427948B1 - 다발성 골수종에서 m-단백질 반응의 임상 평가 - Google Patents

다발성 골수종에서 m-단백질 반응의 임상 평가 Download PDF

Info

Publication number
KR102427948B1
KR102427948B1 KR1020187026496A KR20187026496A KR102427948B1 KR 102427948 B1 KR102427948 B1 KR 102427948B1 KR 1020187026496 A KR1020187026496 A KR 1020187026496A KR 20187026496 A KR20187026496 A KR 20187026496A KR 102427948 B1 KR102427948 B1 KR 102427948B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
ser
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026496A
Other languages
English (en)
Korean (ko)
Other versions
KR20180118151A (ko
Inventor
스테판 하틀
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20180118151A publication Critical patent/KR20180118151A/ko
Application granted granted Critical
Publication of KR102427948B1 publication Critical patent/KR102427948B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G01N33/57426—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ecology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
KR1020187026496A 2016-03-04 2017-03-03 다발성 골수종에서 m-단백질 반응의 임상 평가 Active KR102427948B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16158714.2 2016-03-04
EP16158714 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Publications (2)

Publication Number Publication Date
KR20180118151A KR20180118151A (ko) 2018-10-30
KR102427948B1 true KR102427948B1 (ko) 2022-08-02

Family

ID=55745535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026496A Active KR102427948B1 (ko) 2016-03-04 2017-03-03 다발성 골수종에서 m-단백질 반응의 임상 평가

Country Status (9)

Country Link
US (3) US11618789B2 (enExample)
EP (1) EP3423498A1 (enExample)
JP (5) JP7362250B2 (enExample)
KR (1) KR102427948B1 (enExample)
CN (1) CN108699161B (enExample)
AU (2) AU2017226960B2 (enExample)
IL (2) IL305540B2 (enExample)
SG (1) SG11201806214RA (enExample)
WO (1) WO2017149122A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
CN112513087B (zh) 2018-09-11 2023-01-24 江苏恒瑞医药股份有限公司 抗cd38抗体、其抗原结合片段及医药用途
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
TW202328207A (zh) * 2021-11-29 2023-07-16 德商莫菲西斯公司 減少血清學測定中抗CD38 mAb藥物干擾的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080066741A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20130302318A1 (en) 2010-09-27 2013-11-14 Lisa Rojkjaer Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
PT1853718E (pt) 2005-02-15 2015-11-12 Univ Duke Anticorpos anti-cd19 e usos em oncologia
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
EP2474318A1 (en) * 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JP2014504850A (ja) 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP2831237B1 (en) 2012-03-30 2017-11-29 The Board of Regents of the University of Oklahoma High molecular weight heparosan polymers and methods of production and use thereof
HRP20171964T1 (hr) 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080066741A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20130302318A1 (en) 2010-09-27 2013-11-14 Lisa Rojkjaer Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL

Also Published As

Publication number Publication date
JP7331168B2 (ja) 2023-08-22
US20190077875A1 (en) 2019-03-14
KR20180118151A (ko) 2018-10-30
IL260750B1 (en) 2023-10-01
SG11201806214RA (en) 2018-08-30
JP2026095471A (ja) 2026-06-11
AU2024201503B2 (en) 2026-08-13
AU2024201503A1 (en) 2024-03-28
JP2024169455A (ja) 2024-12-05
JP2022058881A (ja) 2022-04-12
IL305540A (en) 2023-10-01
JP2019513346A (ja) 2019-05-30
IL305540B2 (en) 2024-09-01
AU2017226960B2 (en) 2024-03-21
JP7362250B2 (ja) 2023-10-17
AU2017226960A1 (en) 2018-08-09
JP7835815B2 (ja) 2026-03-25
CN108699161B (zh) 2022-06-03
IL305540B1 (en) 2024-05-01
US20230203189A1 (en) 2023-06-29
CA3016098A1 (en) 2017-09-08
IL260750A (enExample) 2018-09-20
JP2023157927A (ja) 2023-10-26
US20240392034A1 (en) 2024-11-28
CN108699161A (zh) 2018-10-23
EP3423498A1 (en) 2019-01-09
US11618789B2 (en) 2023-04-04
JP7557023B2 (ja) 2024-09-26
WO2017149122A1 (en) 2017-09-08
IL260750B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP7557023B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CN111630068A (zh) 抗cd47抗体及其用途
JP2020508645A (ja) 抗ｃｄ４７抗体およびその使用
JP7239575B2 (ja) サンプル中の自律的に活性なｂ細胞受容体または自律的に活性化されたｂ細胞受容体を認識する方法
CN117343182B (zh) 抗人tigit抗体或其功能性片段及其应用
CN117069848B (zh) 抗人cd146兔单克隆抗体及其应用
WO2023094696A1 (en) Methods for reducing anti-cd38 mab drug interference in serological assays
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2024111419A (ja) 抗体又は抗体フラグメント
CN120441707B (zh) 结合特瑞普利单抗的抗体及其用途
TW201840588A (zh) 抗ｇｐｒ２０抗體
CA3016098C (en) Clinical assessment of m-protein response in multiple myeloma
CN120424221B (zh) 靶向德曲妥珠单抗的抗体及其用途
HK1261804B (en) Clinical assessment of m-protein response in multiple myeloma
HK1261804A1 (en) Clinical assessment of m-protein response in multiple myeloma
CN109593135A (zh) 抗人pd-l1单克隆抗体及其应用
KR102688094B1 (ko) Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
TW201915016A (zh) 單株抗體或其抗原結合片段及其用途
CN120923624A (zh) 可结合人cd137单克隆抗体或其功能性片段及其应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000